We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts... Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com. Show more
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection...
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction...
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 0.558659217877 | 3.58 | 3.7778 | 3.47 | 12679 | 3.57101965 | CS |
4 | -0.55 | -13.2530120482 | 4.15 | 4.249 | 3.47 | 32532 | 3.80660689 | CS |
12 | -7.89 | -68.6684073107 | 11.49 | 21.4599 | 3.47 | 371890 | 8.61506653 | CS |
26 | -18.8 | -83.9285714286 | 22.4 | 61.152 | 3.47 | 3757963 | 43.64544562 | CS |
52 | -22.32 | -86.1111111111 | 25.92 | 61.152 | 3.47 | 2179207 | 41.16281847 | CS |
156 | -3020.4 | -99.880952381 | 3024 | 3680 | 3.47 | 1571513 | 157.92367001 | CS |
260 | -2620.4 | -99.862804878 | 2624 | 5888 | 3.47 | 1362228 | 1057.01504801 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions